Work

P1.01-09 Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598

Year: 2018

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2018.08.565

Authors: M. Boyer, J. Mclean, L. Xu, A. Samkari, D. Carbone

Institutions: Chris O’Brien Lifehouse, Merck & Co., Inc., Rahway, NJ, USA (United States), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2898614308

FWCI: 0.376

Cites:

Cited by: 4

Related to: 10